The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase i and topoisomerase II

Biochemical Pharmacology

Volumn 84, Issue 12, 2012, Pages 1617-1626

  Hasinoff, Brian B ^a   Wu, Xing ^a   Nitiss, John L ^b   Kanagasabai, Ragu ^c   Yalowich, Jack C ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Anticancer; DNA; Dovitinib; Topoisomerase I; Topoisomerase II

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ADENOSINE TRIPHOSPHATASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOVITINIB; PLASMID DNA;

ARTICLE; BINDING SITE; CELL GROWTH; CELL STRAIN K 562; CONTROLLED STUDY; DNA DRUG COMPLEX; DOUBLE STRANDED DNA BREAK; DRUG DNA BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; BENZIMIDAZOLES; DNA; DNA DAMAGE; HUMANS; K562 CELLS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; QUINOLONES; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS; X-RAY DIFFRACTION;

EID: 84869215012     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.09.023     Document Type: Article

References (44)

1. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, and G. Pallares Comprehensive analysis of kinase inhibitor selectivity Nat Biotechnol 29 2011 1046 1051
2. X. Wang, A. Kay, O. Anak, E. Angevin, B. Escudier, and W. Zhou Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib J Clin Pharmacol 2012 10.1177/0091270011433330
3. W.T. Tai, A.L. Cheng, C.W. Shiau, C.Y. Liu, C.H. Ko, and M.W. Lin Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 Mol Cancer Ther 11 2012 452 463
4. T.A. Haystead The purinome, a complex mix of drug and toxicity targets Curr Top Med Chem 6 2006 1117 1127
5. H. Wei, A.J. Ruthenburg, S.K. Bechis, and G.L. Verdine Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase J Biol Chem 280 2005 37041 37047
6. P. Furet, J. Schoepfer, T. Radimerski, and P. Chene Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design: Part I Bioorg Med Chem Lett 19 2009 4014 4017
7. B.B. Hasinoff, and D. Patel The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro Toxicol Appl Pharmacol 249 2010 132 139
8. C. Bailly Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy Chem Rev 112 2012 3611 3640
9. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem Biol 17 2010 421 433
10. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
11. B.L. Staker, M.D. Feese, M. Cushman, Y. Pommier, D. Zembower, and L. Stewart Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex J Med Chem 48 2005 2336 2345
12. J.E. Deweese, and N. Osheroff The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res 37 2009 738 748
13. T.A. Beerman, M.M. McHugh, R. Sigmund, J.W. Lown, K.E. Rao, and Y. Bathini Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities Biochim Biophys Acta 1131 1992 53 61
14. A.Y. Chen, C. Yu, B. Gatto, and L.F. Liu DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors Proc Natl Acad Sci U S A 90 1993 8131 8135
15. K.C. Chow, T.L. Macdonald, and W.E. Ross DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition Mol Pharmacol 34 1988 467 473
16. C.C. Wu, T.K. Li, L. Farh, L.Y. Lin, T.S. Lin, and Y.J. Yu Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333 2011 459 462
17. P. Lassota, G. Singh, and R. Kramer Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors J Biol Chem 271 1996 26418 26423
18. B.H. Long, W.C. Rose, D.M. Vyas, J.A. Matson, and S. Forenza Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles Curr Med Chem Anticancer Agents 2 2002 255 266
19. C. Marminon, F. Anizon, P. Moreau, B. Pfeiffer, A. Pierre, and R.M. Golsteyn Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors Mol Pharmacol 74 2008 1620 1629
20. J. Paradziej-Lukowicz, A. Skwarska, G. Peszynska-Sularz, A. Brillowska-Dabrowska, and J. Konopa Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1 alpha (HIF-1alpha), vascular endothelial growth factor (VEGF) and angiogenesis Cancer Biol Ther 12 2011 586 597
21. R. Prudent, V. Moucadel, C.H. Nguyen, C. Barette, F. Schmidt, and J.C. Florent Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2 Cancer Res 70 2010 9865 9874
22. B.B. Hasinoff, X. Wu, O.V. Krokhin, W. Ens, K.G. Standing, and J.L. Nitiss Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα Mol Pharmacol 67 2005 937 947
23. S.T. Worland, and J.C. Wang Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae J Biol Chem 264 1989 4412 4416
24. A.T. Rogojina, and J.L. Nitiss Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks J Biol Chem 283 2008 29239 29250
25. C. Fattman, W.P. Allan, B.B. Hasinoff, and J.C. Yalowich Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells Biochem Pharmacol 52 1996 635 642
26. R. Zhang, X. Wu, L.J. Guziec, F. Guziec Jr., G-L. Chee, and J.C. Yalowich Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents Bioorg Med Chem 18 2010 3974 3984
27. J.C. Yalowich, X. Wu, R. Zhang, R. Kanagasabai, M. Hornbaker, and B.B. Hasinoff The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα Biochem Pharmacol 84 2012 52 58
28. D.A. Burden, S.J. Froelich-Ammon, and N. Osheroff Topoisomerase II-mediated cleavage of plasmid DNA Methods Mol Biol 95 2001 283 289
29. R. Zhang, X. Wu, J.C. Yalowich, and B.B. Hasinoff Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents Bioorg Med Chem 19 2011 7023 7032
30. J.D. McGhee Theoretical calculations of the helix-coil transition of DNA in the presence of large, cooperatively binding ligands Biopolymers 15 1976 1345 1375
31. B.B. Hasinoff, X. Wu, J.C. Yalowich, V. Goodfellow, R.S. Laufer, and O. Adedayo Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects Anticancer Drugs 17 2006 825 837
32. D. Subramanian, C.S. Furbee, and M.T. Muller ICE Bioassay: isolating in vivo complexes of enzyme to DNA Methods Mol Biol 95 2001 137 147
33. M.C. Vega, I. Garcia Saez, J. Aymami, R. Eritja, G.A. Van der Marel, and J.H. Van Boom Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258 Eur J Biochem 222 1994 721 726
34. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins 52 2003 609 623
35. J.E. Lindsley, and J.C. Wang On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II J Biol Chem 268 1993 8096 9104
36. T.C. Jenkins Optical absorbance and fluorescence techniques for measuring DNA-drug interactions Methods Mol Biol 90 1997 195 218
37. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, and L.F. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468
38. T. Rowe, G. Kupfer, and W. Ross Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage Biochem Pharmacol 34 1985 2483 2487
39. D.R. Pilch, O.A. Sedelnikova, C. Redon, A. Celeste, A. Nussenzweig, and W.M. Bonner Characteristics of γ-H2AX foci at DNA double-strand breaks sites Biochem Cell Biol 81 2003 123 129
40. Y. Pommier, P. Pourquier, Y. Fan, and D. Strumberg Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme Biochim Biophys Acta 1400 1998 83 106
41. M.K. Ritke, W.P. Allan, C. Fattman, N.N. Gunduz, and J.C. Yalowich Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells Mol Pharmacol 46 1994 58 66
42. M.K. Ritke, D. Roberts, W.P. Allan, J. Raymond, V.V. Bergoltz, and J.C. Yalowich Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells Br J Cancer 69 1994 687 697
43. I.H. Segel Enzyme kinetics 1975 John Wiley New York
44. A.B. Shapiro, and B. Andrews Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors Biochem Pharmacol 84 2012 900 904